HEREDITARY ANGIOEDEMA (HAE)
Clinical trials for HEREDITARY ANGIOEDEMA (HAE) explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY ANGIOEDEMA (HAE) trials appear
Sign up with your email to follow new studies for HEREDITARY ANGIOEDEMA (HAE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New study tracks TAKHZYRO's safety for HAE patients in japan
Disease control OngoingThis study looks at the long-term safety and symptom control of TAKHZYRO (lanadelumab) in 155 people with hereditary angioedema (HAE) in Japan. Participants receive the injection as part of their normal care, and doctors monitor side effects and quality of life for 12 months. The…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated May 26, 2026 07:09 UTC
-
New hope for HAE patients: long-term navenibart trial expands
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of a drug called navenibart for people with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. It is open to adults and teens who were in a previous navenibart study. Participants will receive nav…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 07:02 UTC
-
New pill could stop dangerous swelling attacks in hereditary angioedema patients
Disease control ENROLLING_BY_INVITATIONThis study tests an oral medication called deucrictibant for quickly treating sudden swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have completed earlier studies or are new to the drug will take the p…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New shot aims to slash painful swelling attacks for HAE patients
Disease control OngoingThis study tests a new medicine called BW-20805 in 25 adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The goal is to see if the drug can reduce how often these attacks happen over about 6 months. Participants receive the drug and…
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE2 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New daily pill aims to stop HAE attacks in their tracks
Disease control OngoingThis study tests a once-daily pill called deucrictibant to prevent sudden swelling attacks in people aged 12 and older with hereditary angioedema (HAE). Participants will take either the study drug or a placebo for 24 weeks to see if it reduces the number of attacks. The goal is …
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Phase: PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
UK study tracks HAE patients on lanadelumab: fewer attacks expected
Disease control OngoingThis study looks at 50 people in the UK with hereditary angioedema (HAE) who are starting or have started lanadelumab. Researchers will compare the number of swelling attacks in the year before starting the drug to up to two years after. Data comes from medical records, diaries, …
Matched conditions: HEREDITARY ANGIOEDEMA (HAE)
Sponsor: Takeda • Aim: Disease control
Last updated May 18, 2026 12:13 UTC